Erasin is a potent Erlotinib -resistance antagonizing STAT3 inhibitor with IC50s of 9.7 and 24 μM against STAT3 and STAT1, respectively. Erasin induces cancer cells apoptosis.
Erasin inhibits protein-protein interactions mediated by STAT SH2 domains[1].Erasin (0-80 μM; 24 h) induces apoptosis in MDA-MB-231, HCC-827 and Erlotinib -resistant HCC-827 cells[1].
References:
[1]. Lis C, et al. Development of Erasin: a chromone-based STAT3 inhibitor which induces apoptosis in Erlotinib-resistant lung cancer cells. Sci Rep. 2017 Dec 12;7(1):17390.